Compare Roblox Corp (RBLX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Summit Therapeutics Inc — how do they compare? Roblox Corp trades at $44.53 (market cap $32.02B), while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: Roblox Corp is far larger — about 2.3× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| RBLX | SMMT | |
|---|---|---|
Market Cap | $32.02B | $13.79B |
Sector | Media | Health |
52-Week High | $141.56 | $26.38 |
52-Week Low | $35.54 | $12.43 |
Enterprise Value | $30.84B | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RBLX trades at $44.82, up 3.49% today, near the consensus price target of $45.71. The stock shows bullish technical signals with strong support at $43 and resistance at $46. Revenue growth is robust, rising to $4.89B in 2025, but net losses persist at -$1.07B. Recent news highlights regulatory scrutiny in the EU and Australia over child safety, alongside positive economic impact from creator earnings.
Outlook remains mixed: strong revenue growth and cash flow improvement support long-term potential, but profitability challenges and regulatory risks weigh on sentiment. Analysts are divided, with 44.7% recommending buy. The key catalyst is achieving sustained profitability amid expanding user engagement.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
